DKP Critical Insights® Syndicated Reports
DKP has developed a series of syndicated reports to provide perspectives into the oncology and rare-disease environment. The reports are designed to help you inform short- and long-term strategies that will support market positioning of your portfolio, as well as ongoing patient access to care.
State Cancer Drug Parity Legislation – Oral vs. IV
Click here for more information
- Receive quick access to state-specific oral and IV cancer drug parity legislation information
- Identify cost-sharing requirements, limitations, and other provisions for each formulation by state
- Understand how legislative provisions can vary by geography
- Determine whether states with this type of legislation treat oral and IV products equally